Some Investors May Be Worried About Chison Medical Technologies' (SHSE:688358) Returns On Capital
Some Investors May Be Worried About Chison Medical Technologies' (SHSE:688358) Returns On Capital
If we want to find a potential multi-bagger, often there are underlying trends that can provide clues. Typically, we'll want to notice a trend of growing return on capital employed (ROCE) and alongside that, an expanding base of capital employed. Put simply, these types of businesses are compounding machines, meaning they are continually reinvesting their earnings at ever-higher rates of return. Although, when we looked at Chison Medical Technologies (SHSE:688358), it didn't seem to tick all of these boxes.
如果我們想要尋找潛在的多倍收益股,通常會有一些潛在的趨勢可以提供線索。通常,我們會注意到資本回報率(ROCE)不斷增長的趨勢,以及資本利用率擴大的趨勢。簡單來說,這些類型的企業是複利機器,意味着它們不斷以更高的回報率再投資他們的收益。儘管當我們查看祥生醫療(SHSE:688358)時,似乎並未完全符合這些標準。
Return On Capital Employed (ROCE): What Is It?
資本利用率(ROCE)是什麼?
Just to clarify if you're unsure, ROCE is a metric for evaluating how much pre-tax income (in percentage terms) a company earns on the capital invested in its business. The formula for this calculation on Chison Medical Technologies is:
只是爲了澄清,如果您不確定,ROCE是一個評估公司在其業務中投入的資本所賺取的稅前收入比例的指標。這個計算公式適用於祥生醫療:
Return on Capital Employed = Earnings Before Interest and Tax (EBIT) ÷ (Total Assets - Current Liabilities)
資本利用率 = 利息和稅前利潤(EBIT) ÷ (總資產 - 流動負債)
0.056 = CN¥78m ÷ (CN¥1.6b - CN¥200m) (Based on the trailing twelve months to September 2024).
0.056 = 7800萬人民幣 ÷ (16億人民幣 - 2億人民幣)(根據2024年9月止後十二個月)。
Therefore, Chison Medical Technologies has an ROCE of 5.6%. On its own that's a low return on capital but it's in line with the industry's average returns of 6.1%.
因此,祥生醫療的ROCE爲5.6%。獨立來看,這是低資本回報率,但與行業平均回報率6.1%相符。

Above you can see how the current ROCE for Chison Medical Technologies compares to its prior returns on capital, but there's only so much you can tell from the past. If you'd like, you can check out the forecasts from the analysts covering Chison Medical Technologies for free.
您可以查看祥生醫療的當前資本回報率與之前資本回報率的比較,但過去的數據只能告訴您這麼多。如果您願意,您可以免費查看覆蓋祥生醫療的分析師的預測。
What The Trend Of ROCE Can Tell Us
儘管如此,當我們看 enphase energy (納斯達克股票代碼:ENPH) 的時候,它似乎並沒有完全符合這些要求。
On the surface, the trend of ROCE at Chison Medical Technologies doesn't inspire confidence. Over the last five years, returns on capital have decreased to 5.6% from 11% five years ago. On the other hand, the company has been employing more capital without a corresponding improvement in sales in the last year, which could suggest these investments are longer term plays. It's worth keeping an eye on the company's earnings from here on to see if these investments do end up contributing to the bottom line.
從表面上看,祥生醫療的資本回報率趨勢並不令人信心倍增。在過去五年中,資本回報率從五年前的11% 下降至5.6%。另一方面,公司在過去一年中投入了更多資本,但銷售並未相應改善,這可能表明這些投資是長期的策略。繼續關注公司的收益情況,以查看這些投資最終是否有助於底線。
What We Can Learn From Chison Medical Technologies' ROCE
我們從祥生醫療的資本回報率中可以學到什麼
To conclude, we've found that Chison Medical Technologies is reinvesting in the business, but returns have been falling. Unsurprisingly then, the total return to shareholders over the last three years has been flat. In any case, the stock doesn't have these traits of a multi-bagger discussed above, so if that's what you're looking for, we think you'd have more luck elsewhere.
總而言之,我們發現祥生醫療正在對業務進行再投資,但回報率卻在下降。毫不奇怪,過去三年股東的總回報率保持平穩。無論如何,該股並不具備上述多倍增長股的特質,因此如果您在尋找這樣的股票,我們認爲您在其他地方更有可能獲得更大的成功。
On a separate note, we've found 1 warning sign for Chison Medical Technologies you'll probably want to know about.
另外,我們發現祥生醫療存在1個警示信號,你可能希望了解。
While Chison Medical Technologies isn't earning the highest return, check out this free list of companies that are earning high returns on equity with solid balance sheets.
儘管祥生醫療的回報率不是最高的,但請查看這份免費名單,列出了具有穩健資產負債表的公司,這些公司賺取了高回報。
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
對這篇文章有反饋嗎?對內容感到擔憂嗎?請直接與我們聯繫。或者,發送電子郵件至editorial-team @ simplywallst.com。
Simply Wall St的這篇文章是一般性質的。我們僅基於歷史數據和分析師預測提供評論,使用公正的方法,我們的文章並非意在提供財務建議。這並不構成買入或賣出任何股票的建議,並且不考慮您的目標或財務狀況。我們旨在爲您帶來基於基礎數據驅動的長期聚焦分析。請注意,我們的分析可能未考慮最新的價格敏感公司公告或定性材料。Simply Wall St對提及的任何股票都沒有持倉。